XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net loss $ (66,699,593) $ (47,506,869)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,779,999 1,292,696
Amortization of intangible assets 1,214,602 968,986
Change in value of common stock warrants (227,273) 517,334
Stock-based compensation 10,393,812 7,384,318
Amortization of premiums on investments 225,658 200,000
Loss (gain) on short-term investments 77,889 (44,928)
Deferred rent 2,254,122 (125,408)
Loss (gain) on investment in affiliated entity 7,275,462 (5,817,309)
Gain on sale of intangible assets 0 (1,000,000)
Changes in operating assets and liabilities:    
Accounts receivable 9,584,433 (10,122,049)
Accounts receivable from affiliated entity (176,322) 0
Prepaid expenses and other current assets (2,789,784) (473,995)
Prepaid expenses and other current assets from affiliated entity 515,211 (1,086,561)
Other assets (84,035) (811,233)
Accounts payable and accrued expenses 1,119,751 2,949,097
Accrued clinical trial expenses 1,551,656 4,615,783
Accounts payable and accrued expenses due to affiliated entity (289,701) 328,373
Deferred revenue (14,736,401) 1,642,479
Deferred revenue from affiliated entity (250,000) (562,827)
Net cash used in operating activities (49,260,514) (47,652,113)
Cash flows from investing activities:    
Purchases of investments (82,268,656) (42,495,236)
Maturities of investments 49,272,077 51,721,024
Purchases of capital assets (9,415,836) (2,672,235)
Proceeds from sale of intangible assets 0 1,000,000
Purchase of intangible assets and other assets 0 (1,200,000)
Net cash (used in) provided by investing activities (42,412,415) 6,353,553
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 94,347,922 5,458,284
Proceeds from stock option and warrant exercises, net of tax payments 1,466,927 1,607,904
Expenses from other financing activities 0 (149,559)
Net cash provided by financing activities 95,814,849 6,916,629
Increase (decrease) in cash and cash equivalents 4,141,920 (34,381,931)
Cash and cash equivalents, beginning of period 19,136,472 57,632,693
Cash and cash equivalents, end of period 23,278,392 23,250,762
Supplemental disclosure of non-cash activities    
Common stock issued for purchase of intangible and other assets of Bioject 0 4,300,000
Change in amounts accrued for purchases of property and equipment 1,809,948 169,980
Lease incentive recorded as fixed assets and deferred rent $ 0 $ 134,500